BioMarin Pharmaceutical Inc. (BMRN) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en San Rafael, CA, United States. El CEO actual es Alexander Hardy.
BMRN tiene fecha de IPO 1999-07-26, 3,040 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $10.67B.
BioMarin Pharmaceutical Inc. is a biopharmaceutical company that develops and commercializes therapies for rare and life-threatening genetic and metabolic diseases. The company's approved commercial products include Vimizim and Naglazyme for mucopolysaccharidosis disorders, Kuvan and Palynziq for phenylketonuria, Brineura for Batten disease, Voxzogo for achondroplasia, and Aldurazyme for lysosomal storage disease. BioMarin's pipeline includes late-stage gene therapy candidates such as valoctocogene roxaparvovec for hemophilia A and BMN 307 for phenylketonuria, along with BMN 255 in development for primary hyperoxaluria. The company distributes its products globally through specialty pharmacies, hospitals, and pharmaceutical wholesalers across the United States, Europe, Latin America, and international markets, while maintaining strategic partnerships with leading biotechnology firms.
